AOD-9604 vs Noopept
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | Noopept |
|---|---|---|
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. |
| Best For |